Akebia Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Akebia Therapeutics Inc AKBA.OQ reported quarterly breakeven results​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -4 cents. The mean expectation of five analysts for the quarter was for a loss of 2 cents per share. Wall Street expected results to range from -4 cents to -1 cents per share.

• Revenue rose 43.1% to $62.47 million from a year ago; analysts expected $47.24 million.

• Akebia Therapeutics Inc's reported EPS for the quarter was breakeven results​.

• The company reported quarterly net income of $247 thousand.

• Akebia Therapeutics Inc shares had risen by 4.0% this quarter and gained 99.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 33.3% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Akebia Therapeutics Inc is $7.00, about 45.9% above its last closing price of $3.79

This summary was machine generated from LSEG data August 7 at 06:27 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)